Gaucher Disease Treatment Market to register US $2.11 Bn by 2025

July 24, 2019

Global Gaucher Disease Treatment Market is anticipated to reach US $2.11 billion by 2025, according to the latest research available at Market Study Report LLC, report provides extensively data on market share, growth, trends and forecasts for the period 2017-2025.

According to the study, Gaucher disease treatment market is mainly driven by increasing prevalence of the disease in men & women across all ages, and a subsequent rise in number of drugs made available in the market. Rising investments made by research institutes and market leaders for developing new drugs that help in treating Type II & Type III Gaucher will supplement industry growth. Moreover, government initiatives focused on creating awareness regarding Gaucher disease would complement market growth over the coming years. 

Based on disease type, the global Gaucher disease treatment market is categorized into Type I, Type II, and Type III Gaucher. As per the report, the type I Gaucher disease has emerged as a dominating market segment owing to increasing number of cases being registered worldwide. According to the National Gaucher Foundation (NGF), type I Gaucher is said to affect around 95% of the population, making it one the most common disease type worldwide.

Based on treatment type, the Gaucher disease treatment market is segmented into Substrate Reduction Treatment (SBT) and Enzyme Replacement Therapy (ERT). The study estimates that ERT segment will hold a dominating position in the market over the forecast period. In 2017, the segment recorded the highest revenue share and captured a substantial share of the market. Moreover, the increased use of ERT for treating Gaucher disease worldwide and growing awareness regarding ERT, will augment Gaucher disease treatment market share in the ensuing years.

Request sample copy of this Report@

As per geographical analysis, the global Gaucher disease treatment market is segmented into five major regions, namely North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. Reportedly, North America is projected to capture the highest market share, owing to growing prevalence of Gaucher in the region, unmeet clinical needs, and rising awareness and use of effective treatment options.

Meanwhile, major firms operating in Gaucher disease treatment market include Pfizer Inc., Sanofi (Genzyme Corp.), Shire Human Genetics Therapies, Inc., Acetelion Pharmaceutical (J&J Ltd.), Erad Therapeutics Inc., and JCR Pharmaceuticals Co Ltd. The company profiles of leading firms are mentioned in the report alongside their business overview, product benchmarking, financials, and recent developments.

The report offers a brief synopsis of Gaucher disease treatment market with respect to Porter’s five forces, industry trends, market forces, ecosystem analysis, and PEST analysis. It also provides an all-embracing quantitative and qualitative analysis of potential industry trends and growth prospects between 2017-2025.